-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Short Interest Down 49.3% in August
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Short Interest Down 49.3% in August
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the August 15th total of 7,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.8 days.
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC grew its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after buying an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent SEC filing. Institutional investors own 2.94% of the company's stock.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Stock Performance
Calliditas Therapeutics AB (publ) stock opened at $15.95 on Thursday. The stock has a market cap of $471.73 million, a P/E ratio of -6.40 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $18.07 and a 200-day moving average of $17.74. Calliditas Therapeutics AB has a 52 week low of $12.55 and a 52 week high of $27.50.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on CALT shares. Kepler Capital Markets started coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They issued a "buy" rating for the company. TheStreet cut Calliditas Therapeutics AB (publ) from a "c-" rating to a "d" rating in a report on Tuesday, September 6th. Finally, Pareto Securities assumed coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They issued a "buy" rating for the company.About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Featured Articles
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the August 15th total of 7,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.8 days.
卡利迪塔斯治療公司(PUBL)(納斯達克代碼：CALT-GET評級)是8月份空頭股數銷量大幅下降的接受者。截至8月31日，空頭股數共有3600股，比8月15日的7100股減少了49.3%。以4,300股的平均成交量計算，目前天數與回補比率為0.8天。
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
對衝基金買入Calliditas Treateutics AB(Publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC grew its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after buying an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent SEC filing. Institutional investors own 2.94% of the company's stock.
一家機構投資者最近提高了對Calliditas Treateutics AB(Publ)股票的頭寸。根據最近提交給美國證券交易委員會的13F文件，鐵木投資管理公司在第一季度增持了Calliditas Treateutics AB(Publ)(納斯達克代碼：CALT-GET評級)的股票5.5%。該基金在本季度額外購買了1,495股後，持有該公司28,762股股票。截至最近提交給美國證券交易委員會的文件，Ironwood Investment Management LLC擁有Calliditas Treateutics AB(Publ)0.11%的股份，價值551,000美元。機構投資者持有該公司2.94%的股票。
Calliditas Therapeutics AB (publ) Stock Performance
Calliditas Treateutics AB(Publ)股票表現
Calliditas Therapeutics AB (publ) stock opened at $15.95 on Thursday. The stock has a market cap of $471.73 million, a P/E ratio of -6.40 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $18.07 and a 200-day moving average of $17.74. Calliditas Therapeutics AB has a 52 week low of $12.55 and a 52 week high of $27.50.
週四，Calliditas Treateutics AB(Publ)的股票開盤報15.95美元。該股市值為4.7173億美元，市盈率為-6.40，貝塔係數為1.63。該公司的流動比率為5.32，速動比率為5.32，債務權益比率為0.64。該股的50日移動均線切入位為18.07美元，200日移動均線切入位為17.74美元。Calliditas Treateutics AB的52周低點為12.55美元，52周高點為27.50美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
About Calliditas Therapeutics AB (publ)
關於Calliditas Treateutics AB(Publ)
(Get Rating)
(獲取評級)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家臨牀階段的生物製藥公司，專注於識別、開發和商業化用於孤兒適應症治療的藥物產品，最初的重點是腎臟和肝臟疾病。它提供Nefecon，一種口服布地奈德製劑，是一種治療自身免疫性腎病免疫球蛋白A腎病的免疫抑制劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- 免費獲取StockNews.com關於Calliditas Treateutics AB(Publ)(CALT)的研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 具有有趣內幕活動的四隻廉價股票
- 隨着收購傳言的甚囂塵上，Lyft能否成功？
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新聞和評級-在下面輸入您的電子郵件地址，以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Calliditas Treateutics AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧